A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL

Summary

The study is designed as a Phase III, double-blind, multicenter, randomized, active-controlled, parallel-group design in which two groups of participants will receive either SII-YFV or STAMARIL® - a licensed and WHO pre-qualified YFV. The study will start only after the approval from the applicable ethics committees and national regulatory agencies.

Timeline

Start

2023-05-11

Primary completion

2024-05-10

Completion

2024-05-10

Drugs

Indications